Alexander KarpAlexander Karp earned $1B in 2024

In 2023, Gilmore O’Neill earned $3.24M in total compensation at Editas Medicine, including $641.09K salary, $392.54K bonus and $2.19M in stock. 3+ years at the helm of Editas Medicine.

Compensation History

Annual executive compensation data for Gilmore O’Neill, including salary, bonuses, and stock awards.

Year

2023

Total Compensation

$3.24M

Salary

$641.09K

Bonus

$392.54K

Other

$7.29K

Salary

$641.09K

Board Justification

The compensation philosophy is designed to attract and retain qualified executives, motivate them to achieve business goals, and reward them for performance. It emphasizes a significant portion of performance-based compensation.

Bonus

$392.54K

Board Justification

The annual performance-based cash bonus for Dr. O’Neill was determined solely based on the achievement of corporate goals and his target bonus amount, as determined by our Board, and pursuant to the terms of his offer letter.

Other Compensation

$7.29K

Board Justification

Other compensation includes life insurance premiums and 401(k) matching contributions.

Restricted Stock

$2.19M216.64K RSU

Board Justification

The stock awards granted to Dr. O’Neill that vested in 2023 were performance-based restricted stock units (PSUs) that vest upon the achievement of certain research and development milestones.

Performance Metrics

The performance metrics for Dr. O’Neill's compensation were based on corporate performance goals, with a corporate achievement percentage of 102% for 2023.

E

Gilmore O’Neill

CEO of Editas Medicine

Education

Ph.D. in Biomedical Engineering from the University of California, San Diego.

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

CEO of Editas Medicine for

3 years 6 months (Jun 2022 - Present)

Previous Experience

Various leadership roles in biotechnology and healthcare.

Holdings

Track Gilmore O’Neill's stock holdings and portfolio value over time.

Insider Trading

Gilmore O’Neill's recent stock transactions, purchases, and sales filed with the SEC.

No insider trades found for this CEO.

Rivals

Compare Gilmore O’Neill with competitor CEOs and industry peers.